Sandra De Meyer, Inge Dierynck, Anne Ghys, Maria Beumont, Bjorn Daems, Ben Van Baelen, James C. Sullivan, Douglas J. Bartels, Tara L.
Zhenyu Xu, Yue Wang, Houqi Liu – 14 July 2012
Kathleen O'sullivan, John Levis, Kevin Hegarty, Orla Crosbie, Elizabeth Kenny‐Walsh, Liam J. Fanning – 14 July 2012
Patrick R. Harrington, Lisa K. Naeger, Wen Zeng – 14 July 2012
Norio Akuta, Fumitaka Suzuki, Yuya Seko, Yusuke Kawamura, Hitomi Sezaki, Yoshiyuki Suzuki, Tetsuya Hosaka, Masahiro Kobayashi, Tasuku Hara, Mariko Kobayashi, Satoshi Saitoh, Yasuji Arase, Kenji Ikeda, Hiromitsu Kumada – 14 July 2012 – The impact of amino acid (aa) 70 substitution in the core region on hepatocarcinogenesis and survival for liver‐related death in patients of hepatitis C virus (HCV) genotype 1b (HCV‐1b), who had not received antiviral therapy, is unknown. The relationships among aa 70 substitution, IL28B genotype, and hepatocarcinogenesis are also not clear.
Ewan H. Forrest, Michael R. Lucey – 14 July 2012
Tomonori Aoyama, Yong‐Han Paik, Sumio Watanabe, Benoît Laleu, Francesca Gaggini, Laetitia Fioraso‐Cartier, Sophie Molango, Freddy Heitz, Cédric Merlot, Cédric Szyndralewiez, Patrick Page, David A. Brenner – 14 July 2012 – Nicotinamide adenine dinucleotide phosphate (NADPH) oxidase (NOX) generates reactive oxygen species (ROS) in hepatic stellate cells (HSCs) during liver fibrosis. In response to fibrogenic agonists, such as angiotensin II (Ang II), the NOX1 components form an active complex, including Ras‐related botulinum toxin substrate 1 (Rac1).
Michael E. Mullins, Evan Schwarz – 14 July 2012
Massimo Puoti, Maria Cristina Moioli, Roberto Rossotti, Giovanna Travi, Raffaele Bruno – 14 July 2012
Shaoyong Li, Lianne E.M. Vriend, Imad A. Nasser, Yury Popov, Nezam H. Afdhal, Margaret J. Koziel, Detlef Schuppan, Mark A. Exley, Nadia Alatrakchi – 14 July 2012 – Hepatitis C virus (HCV)‐specific immune effector responses can cause liver damage in chronic infection. Hepatic stellate cells (HSC) are the main effectors of liver fibrosis. TGFβ, produced by HCV‐specific CD8+ T cells, is a key regulatory cytokine modulating HCV‐specific effector T cells.